Phase 1 N=29 Dose Finding Study of BI 836880 in Patients With Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 720 Milligram
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=69 Monotherapy Dose Finding With BI 847325 in Solid Tumours
Neoplasms
Primary: Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study — 0; 0; 0; 0 Percentage of participants
Phase 1 N=27 An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Cancer: Solid Tumors
Primary: Maximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a Day — 13 mg BID
Phase 1 N=110 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Neoplasms
Primary: Phase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks) — 0; 0; 0 Participants
Phase 1 N=24 Weekly BI 836880 in Patients With Advanced Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
N/A N=31 Radiation Dose Escalation in Esophageal Cancer
Esophageal Cancer
Primary: Number of Dose Limiting Toxicities (DLTs) Occurring in Participants — 0; 0; 0; 1 dose limiting toxicity
Phase 2 N=111 Sym004 in Patients With Advanced Solid Tumors
Metastatic Colorectal Cancer
Primary: Number of Participants With Adverse Events (AEs) — 20; 29; 13; 12 Participants
Phase 1 N=43 A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 4; 3; 13; 3 Participants
Phase 1 N=120 Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Endometrial Adenocarcinomas · Neuroendocrine Tumors · Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Primary: Maximum Tolerated Dose (MTD) — 50; 50; 5.0; 5.0 DOX mg/m2 PM01183 mg FD
Phase 1 N=31 Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
Melanoma · Cancer
Primary: Number and Percentage of Patients With Dose Limiting Toxicities (DLT). — 0; 0; 0; 0 Participants
Phase 1 N=31 Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
Solid Tumors
Primary: Recommended Phase 2 Dose — NA; NA; NA; NA micrograms per milliliter (μg/mL)
Phase 1 N=35 A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
Cancer
Primary: Number of Participants With Adverse Events — 3; 3; 5; 3 Participants
Phase 1 N=6 Intratumoral Cisplatin for Resectable NSCLC
Non-Small Cell Lung Cancer
Primary: Rate of Dose Limiting Toxicity — 0 participants
Phase 1 N=64 Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Solid Tumors
Primary: Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 18; 6; 7 Participants
Phase 1 N=104 Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)
Locally Advanced Tumors · Metastatic Solid Tumors · Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0; 0 Participants
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
Phase 1 N=39 A Study of IMC-RON8 in Advanced Solid Tumors
Cancer
Primary: Maximum Tolerated Dose (MTD) of IMC-RON8 — NA mg/kg
Phase 2 N=176 Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
Cancer
Primary: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability — 24; 83; 33; 18 participants
Phase 1 N=147 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Part 1 · MELANOMA · SCCHN
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 — 0; 0; 0; 0 Percentage of Participants
Phase 1 N=44 A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Neoplasms
Primary: Number of Participants With Adverse Events (AEs) — 6; 3; 3; 11 Participants
Phase 1 N=125 Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
Metastatic Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of TAK-117 — 150; 900; 900; NA mg
Phase 1 N=21 Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of Xentuzumab in Japanese Patients With Advanced Solid Tumours, as Identified by the Number of Patients With Dose-limiting Toxicities (DLTs)…
Phase 1 N=25 Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
Solid Tumors · Non-Hodgkin's Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Efavirenz — 1200 mg
Phase 1 N=44 Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Advanced Solid Tumors
Primary: Objective Response Rate and Duration — 0; 0; 0; 0 participants with objective response
Phase 1 N=149 First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Primary: Number of Subjects With Any Dose Limiting Toxicity (DLT) — 1; 3; 2 subjects
Phase 1 N=32 Study of E7389 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Determination of the Maximum Tolerated Dose — 1.0 mg/m^2
Phase 1 N=19 Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) of CPX-POM — 0; 0; 0; 0 participants
Phase 1 N=64 Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
Neoplasms
Primary: Maximum Tolerated Dose (MTD) or Relevant Biological Dose (RBD) of BI 836845 During the First Treatment Course of the Dose Escalation Phase — 1000 mg
Phase 1 N=41 An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
Advanced Solid Tumors
Primary: Treatment Phase Part A: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for E7820 — 12500; 11500 nanogram*hour per milliliter (ng*hr/mL)
Phase 1 N=82 An Open Label Dose Escalation Study Of E7080
Solid Tumor or Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 25 milligram (mg)